Home
overview

SMi Group announces the 9th Annual RNA Therapeutics Conference in London on February 21st - 22nd 2018. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.* (Source: https://www.alliedmarketresearch.com/RNA-based-therapeutics-market)


One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they’ve learnt whilst developing an RNA therapeutic.


Join us in February 2018, as SMi’s RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to analyze and evaluate the latest advancements in RNA therapeutics, including SaRNA as a potential therapeutic for people with liver cancer, advances in targeted delivery of nucleotides beyond the liver and the latest developments in delivery systems, such as exosomes and nanocomplexes.
 


Networking Opportunities: We keep networking at the forefront when it comes to our events. With over 4 hours of networking included in the event, there will be multiple opportunities to interact with the key industry leaders within the RNA Therapeutics.
 

The Agenda: Discover the latest trends and hottest topics in the industry included with the packed agenda.


Location/Venue
: Being held in the heart of London, Holiday Inn Kensington Forum is perfectly located to explore London from.

Knowledgeable events team: Onsite staff will provide you with an exceptional service. They will answer any questions you may have and inform you about any changes to the agenda, to ensure the event runs smoothly.

 
The Conference:
Explore new strategies being utilized by industry professionals and scientific pioneers
Establish the latest developments and advancements in RNA delivery agents and RNA-based therapeutics
Evaluate clinical results and lesson that have been learnt during clinical trials, through case studies with leading RNA therapeutics companies
Enhance knowledge regarding patenting of therapeutics, in order to maximise commercial return
Hear from the MHRA about potential new and upcoming regulatory updates and how they might affect the industry
 

Key Job Titles include:

  • Research & Development Directors/Managers/Scientists
  • Senior Scientists
  • Chief Scientific Officers
  • Chief Medical Officers
  • Heads of Clinical Development
  • Heads of Pre-Clinical Development

Global Presence: 

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.

Companies include:

Admedus Immunotherapies | AstraZeneca | Bayer AG | BioNTech | CureVac | Diamond Biopharm | Dicerna Pharmaceuticals | Exicure Inc. | Exiqon | GlobalAcorn Ltd | GSK | Imperial College London | Lipocalyx | Merck | MHRA | Mundipharma International Ltd | Novartis Institutes for Biomedical Research  | Quark Pharmaceuticals Inc. | Roche A / S | Sanofi | Silence Therapeutics GmbH | Silenseed | SilverRNA | Storm Therapeutics | ThermoFisher | Valneva | Yuria Pharma

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Nagy Habib

Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics
View Bio

9:10 Utilising Small Activating RNA (saRNA) for Therapeutic Opportunities

Nagy Habib

Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics
View Bio

• Harnessing the innate mechanism of gene activation
• Evaluating how saRNA can be used to restore the expression of CCAAT/enhancer binding protein alpha (C/EBP-a)
• Achieving proof of concept: Clinical applications and therapeutic opportunities this offers
• Lessons learnt during Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer

9:50 Progress in RNA therapeutics for patients with cystic fibrosis

Noreen Henig

Noreen Henig, Chief Medical Officer, ProQR Therapeutics BV
View Bio

• Opportunities for RNA therapeutics in patients with cystic fibrosis
• Evidence for QR-010 as a meaningful RNA therapeutic for patients with cystic fibrosis due to the F508del mutation
• Potential RNA therapeutic approaches for patients with cystic fibrosis due to other mutations
 

10:30 Morning Coffee

11:00 MicroRNA Therapeutics: Opportunities and Challenges for Targeting the Pathways of Human Disease

Ekkehard Leberer

Ekkehard Leberer, Senior Director , Sanofi
View Bio

• MicroRNAs regulate by the mechanism of RNA interference (RNAi) biochemical pathways involved in human diseases
• MicroRNA-21 has been implicated in multiple organs with fibrosis and cancer
• The presentation will summarize opportunities and challenges of developing microRNA based oligonucleotide therapeutics and illustrate the generation of an anti-fibrotic oligonucleotide drug targeting microRNA-21
 

11:40 miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells

Elena Bichenkova

Elena Bichenkova, Senior Lecturer in Medicinal Chemistry, Manchester University
View Bio

• The key challenges in the traditional DDD process of small molecule drugs
• Some emerging  opportunities in attempt to overcome the key issues
• New avenues for development of novel therapeutic interventions against cancer
• Development of ‘intelligent’ anti-cancer therapeutics against oncogenic microRNAs

12:20 Networking Lunch

13:30 Developing mRNA therapeutics for Skin Diseases

Markus  Mandler

Markus Mandler , Chief Scientific Officer, Accanis
View Bio

• Skin offers various opportunities with regard to development of mRNA-based therapeutics: diseases with validated molecular targets/attractive markets and direct access facilitating quantification of mRNA expression/clinical activity
• mRNA is a new drug format capable of exceeding existing protein-based therapeutics.
• Developing proprietary IVT-mRNAs addressing validated targets for specific skin conditions
• Systematically modifying specific IVT-mRNAs and testing the most interesting ones in skin explant systems varying formulation and delivery.
 

14:10 Self-amplifying mRNA vaccines

Jeffrey Ulmer

Jeffrey Ulmer, Head Preclinical R&D, GSK
View Bio

• Evaluating the new vaccine technology known as SAM (self-amplifying mRNA)
• Utilising mRNA research alongside recombinant adenoviral vector technology
• Case study: Lessons learnt when attempting to develop a Zika vaccine
 

14:50 Afternoon Tea

15:20 Using mRNA technology in the development of novel cancer vaccines

Birgit  Pless

Birgit Pless, Deputy Head of Project Management, BioNTech AG
View Bio

16:00 Harnessing the power of RNA Epigenetics – targeting RNA modifying enzymes for the treatment of cancer

Oliver Rausch

Oliver Rausch, VP Research & Development , Storm Therapeutics
View Bio

• Over 150 different chemical modifications have been identified on RNA molecules.
• The role of these modifications in the maturation and regulation of coding and non-coding RNA is becoming increasingly prominent.
• Utilising the research of world-leading founders Professors Kouzarides and Miska in the field of RNA epigenetics to pioneer the development of small molecule inhibitors of previously untargeted RNA-modifying enzymes (RMEs) to interfere with key RNA pathways and mechanisms
 

16:40 RNAoptimizer – From mRNA to product

Mariola Fotin-Mleczek

Mariola Fotin-Mleczek, Chief Scientific Officer., CureVac GmbH
View Bio

• CureVac’s RNAoptimizer provides optimal mRNA for each target indication
• The RNAoptimizer includes sequence optimization, formulation & delivery adjustment and protein design improvement
• RNAoptimizer is developed as robotic assisted process
 

17:20 Chairman’s Closing Remarks and Close of Day One

Nagy Habib

Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics
View Bio

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Shalini  Andersson

Shalini Andersson, Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D
View Bio

9:10 Gaining Regulatory Approval and Mitigating Risks during Clinical Trials

Kirsty Wydenbach

Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, Medicines and Healthcare products Regulatory Agency
View Bio

• Expectations of a regulator and how to report your results 
• Overcoming common governing pitfalls
• Updates of new and upcoming regulations and how you may be affected

9:50 Patenting RNA Therapeutics

James  Ogle

James Ogle, European Patent Attorney and UK Chartered Patent Attorney, Hoffmann Eitle
View Bio

• Drafting a successful new patent application
• Advice regarding oppositions and appeals before the European Patent Office
• Avoiding risks associated with patents, including patent infringement and patent transactions
• Moving beyond compound protection, which types of follow-up protection should be considered by innovators
 

10:30 Morning Coffee

11:00 Local and Systemic Oligonucleotide Delivery Using RALA Peptide Nanoparticles

Helen  McCarthy

Helen McCarthy, Chair of Nanomedicine, Queen’s University Belfast’s, School of Pharmacy
View Bio

•  High Transfection Efficiency with Low Associated Toxicity
•  Tunable Systemic In Vivo Biodistribution
•  Ability to Concentrate into Tumours/Cancer Cells
•  Simple, Easy to Use Formulation and Scale Up
 

11:40 Advances in Targeted Delivery of Nucleotides Beyond the Liver

Shalini  Andersson

Shalini Andersson, Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D
View Bio

• Potential targeting approaches for delivery to tissues and cell types beyond the liver, including the cardiovascular, metabolic and renal systems
• Overcoming challenges, including insufficient pharmacokinetic properties and poor cellular uptake
• Evaluation of the drugs in the pipeline for AstraZeneca

12:20 Viromer preclinical validation

Steffen Panzner

Steffen Panzner, Managing Director, Lipocalyx
View Bio

• The Viromer technology
• Optimization both for Chemistry and Formulation
• Application in Preclinical Models
 

13:00 Networking Lunch

14:10 Utilising an alternative siRNA delivery approaches to target liver hepatocytes

Bob Brown

Bob Brown , CSO and SVP Research & Development, Dicerna Pharmaceuticals Inc.
View Bio

• Advantages of using GalXC RNAi platform delivery approach over a traditional Lipid Nanoparticle (LNP) Delivery System
• Chemistry and challenges of this platform
• Advantages of using Dicer Substrate short-interfering RNAs (DsiRNAs), for targeted therapies
• Case study: Dicerna’s drug pipeline and pre-clinical trials, which utilize the alternative delivery approach to treat disease
 

14:50 The Evolution of RNAi Delivery at Arrowhead

James Hamilton

James Hamilton , Vice President Clinical Development, Arrowhead Pharmaceuticals, Inc.
View Bio

• Older RNAi delivery technologies
• Dynamic Polyconjugates: Pre-clinical and Clinical Experience
• Arrowhead Single Molecule RNAi Conjugates
 

15:30 Afternoon Tea

16:00 Unlocking the potential of nucleic acid therapeutics using Spherical Nucleic Acids

David Giljohann

David Giljohann, CEO, Exicure Inc.
View Bio

• Spherical Nucleic Acid (SNA™) are nanoscale, spherical arrangements of densely packed and radially oriented nucleic acids
• Localization to endosome permits large numbers of SNA’s to be delivered with low toxicity
• By activating innate immune cells, SNA’s enhance the function and secretion of cytokines
• AST-008 is a TLR9 agonist oligonucleotide in SNA format which demonstrates greater delivery to primary cells and more potent TLR9 activation in cell-based assays:

  • AST-008 has been evaluated in numerous solid and liquid tumor models, including breast, colon, bladder, melanoma and lymphoma
  • Combining AST-008 with a checkpoint inhibitor (PD-1) and IDO inhibitors results in a profound impact on tumor growth and survival
  • AST-008 clinical trial progress will be discussed

     

  • 16:40 Exploiting Exosomes for therapeutic and diagnostic applications

    Samir EL Andaloussi

    Samir EL Andaloussi, Assistant Professor , Karolinska Institutet
    View Bio

    • Examining the translational applications of exosome research, including biomarker discovery and drug delivery
    • Consideration and evaluation of the important advantages compared to other nanoparticulate drug delivery systems
    • Overcoming potential problems with component characterization and immune reactions
     

    17:20 Delivery of a MYCN siRNA Therapy to Neuroblastoma by a Targeted Nanocomplex

    Stephen Hart

    Stephen Hart, Professor in Molecular Genetics, University College London
    View Bio

    • Neuroblastoma is a tumour of nerves with primary tumours usually located in the abdomen.
    • Neuroblastoma is the most common solid tumour in childhood with worst prognosis cases involving amplification of the MYCN proto-oncogene.
    • Silencing of MYCN induces differentiation, apoptosis leading to tumour eradication or slow growth.
    • Integrin-targeted, lipid-peptide nanocomplexes enable systemic delivery to neuroblastoma tumours specifically, avoiding uptake by liver and other organs.
     

    18:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Bob Brown

    Bob Brown

    CSO and SVP Research & Development, Dicerna Pharmaceuticals Inc.
    David Giljohann

    David Giljohann

    CEO, Exicure Inc.
    James Hamilton

    James Hamilton

    Vice President Clinical Development, Arrowhead Pharmaceuticals, Inc.
    Mariola Fotin-Mleczek

    Mariola Fotin-Mleczek

    Chief Scientific Officer., CureVac GmbH
    Nagy Habib

    Nagy Habib

    Chairman and Co-Founder, MiNA Therapeutics
    Noreen Henig

    Noreen Henig

    Chief Medical Officer, ProQR Therapeutics BV
    Shalini  Andersson

    Shalini Andersson

    Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D

    Birgit Pless

    Deputy Head of Project Management, BioNTech AG
    Birgit  Pless

    Birgit Pless studied Biology at the Free University Berlin. She was a PhD Student through a scholarship from the Frankfurt International School for Translational Biomedicine at the Goethe University, Frankfurt (2008-2011), in the Pharmaceutical Biology Department with Prof. Dr. Rolf Marschalek about acute lymphoblastic leukemia.
    Since 2011, she has been employed as a Project manager by BioNTech Managing Clinical Projects.
     

    Bob Brown

    CSO and SVP Research & Development, Dicerna Pharmaceuticals Inc.
    Bob Brown

    Bob Brown joined Dicerna as Senior Vice President, Research in 2008. Prior to joining Dicerna, he had a long career at Genta, where he was Vice President, Research and Technology and had more than 75 issued patents and patent applications.

    While at Genta, Bob became one of the only R&D executives in biotechnology industry to follow a systemically administered oligonucleotide therapeutic (Genasense™) from research bench through Phase 1, 2 and 3 clinical trials and NDA review. He worked directly with clinicians and study investigators on trial design, execution and interpretation of results. In addition to his roles at Genta, Bob was Co-founder and Vice President of Research and Development at Oasis Biosciences.

    Bob holds a Ph.D. in molecular biology from the University of California, Berkeley, and B.S. degrees in chemistry and biology from the University of Washington.
     

    David Giljohann

    CEO, Exicure Inc.
    David Giljohann

    David Giljohann is the CEO of Exicure, Inc., a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin at Northwestern University where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition.

    Ekkehard Leberer

    Senior Director , Sanofi
    Ekkehard Leberer

    Dr. Leberer received his Ph.D. in Biology at the University of Konstanz, Germany (1986). He conducted post-doctoral training in molecular biology at the Banting and Best Institute of the University of Toronto, Canada, and then became a Professor of Biochemistry at the University of Konstanz, Germany (1992). He is currently responsible for R&D Alliance Management at Sanofi, and is the Scientific Managing Director of the Innovative Medicine Initiative COMPACT Consortium on the delivery of biopharmaceuticals across biological barriers and cellular membranes (www.compact-research.org).
    Since joining Hoechst Marion Roussel in 1998, Dr. Leberer carried out various managing roles in this company, Sanofi’s predecessor companies and Sanofi itself, including responsibilities in functional genomics, biological sciences and external innovation for oligonucleotide-based therapeutics. He has also served as Head of Biotechnology Germany and a member of the Scientific Review Committee of Aventis Pharma Germany.
    Prior to joining pharmaceutical industry, Dr. Leberer served as Senior Research Officer in genetics and genomics at the Biotechnology Research Institute, National Research Council of Canada, Montreal. His research has focused on the molecular mechanisms of signal transduction and the role of signalling molecules in human diseases. He is the principal discoverer of the p21 activated protein kinase (PAK) family of cell signalling proteins and of novel virulence-inducing genes in pathogenic fungi. He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.
     

    Elena Bichenkova

    Senior Lecturer in Medicinal Chemistry, Manchester University
    Elena Bichenkova

    Having graduated in Chemistry (BSc - 1981; MSc - 1983) with a PhD in NMR structural biology (1993, Russia), Elena continued her research in the USA at Purdue University (1992, 1994) and then at the University of Texas (1996) collaborating with the first-rank NMR laboratory of Prof. David Gorenstein. After being awarded a Royal Society/NATO Postdoctoral Fellowship in 1996, she joined the University of Manchester as a Research Fellow. In January 2004 Elena was appointed by Manchester Pharmacy School as a Lecturer in Medicinal Chemistry followed by promotion to Senior Lecturer (2009) and then to Reader (2013).
     

    Helen McCarthy

    Chair of Nanomedicine, Queen’s University Belfast’s, School of Pharmacy
    Helen  McCarthy

    Professor McCarthy is the Chair of Nanomedicine at Queen’s University Belfast’s School of Pharmacy. As such McCarthy comes from an environment where 11 products have been commercialized. At Queen’s University Belfast, Helen leads a lab of 3 post-doctoral researchers and 6 PhD students where she has been specializing in peptide based drug delivery systems. To that point, she is the inventor of the RALA peptide and further innovations that allow for full bio-distribution and cancer targeting using a peptide based drug delivery system. Over the past 11 years, her work with the RALA peptide has been the refinement of the nanoparticle system and generation of numerous in vivo proof-of-concept studies showing potential in nucleic acid delivery as well as a more recent demonstrations with anionic small molecules such as nucleotides and bisphosphonates.

    James Ogle

    European Patent Attorney and UK Chartered Patent Attorney, Hoffmann Eitle
    James  Ogle

    James Ogle, PhD, is a European and UK patent attorney, and partner at pan-European law firm Hoffmann Eitle. Dr. Ogle acts for clients across the life sciences, with broad experience in RNA-based technologies. Much of his work focuses on oppositions and appeals at the European Patent Office, and also includes advice on new inventions, drafting/prosecuting patent applications, patent-related due diligence, SPCs, and aspects of pan-European litigation. Dr. Ogle graduated from Regensburg University (Germany) in 2000 and obtained his PhD at Cambridge University (UK) with Venki Ramakrishnan in 2004, on research on mRNA translation closely connected with Ramakrishnan’s 2009 Nobel Prize.

    James Hamilton

    Vice President Clinical Development, Arrowhead Pharmaceuticals, Inc.
    James Hamilton

    Dr. James Hamilton currently serves as Vice President Clinical Development at Arrowhead Pharmaceuticals where he is responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led Arrowhead’s acquisition of the Novartis RNAi assets and led Arrowhead’s $670 Million cardiovascular deal with Amgen. Dr. Hamilton previously served as CEO of Calando Pharmaceuticals. He earned an MD and MBA at The Ohio State University and is board certified in Emergency Medicine.

    Jeffrey Ulmer

    Head Preclinical R&D, GSK
    Jeffrey Ulmer

    Dr. Jeffrey Ulmer received his B.Sc. with honours from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories, Chiron Corporation and Novartis Vaccines he conducted seminal studies on nucleic acid vaccines and novel vaccine adjuvants/delivery systems. He has published over 200 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy, Human Vaccines, and Expert Review of Vaccines. He is currently Head, Preclinical R&D, GSK Vaccines.

     

     

     

     

     

     

     

     


     

    Kirsty Wydenbach

    Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, Medicines and Healthcare products Regulatory Agency
    Kirsty Wydenbach

    Kirsty joined the MHRA in 2009 as a Medical Assessor in the Clinical Trials Unit. She has been specifically involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including trials for both chemical and biological products, Advanced Therapy Products and many first-in-man studies. She has also been involved in European discussions aiming to establish an EU harmonised approach to decisions regarding clinical trials, particularly for Developmental Safety Update Reports (DSURs) and also including Voluntary Harmonised Procedure (VHP) applications. More recent EU priorities have included the new Clinical Trial Regulation and Kirsty currently sits on the safety subgroup of the Clinical Trials Facilitation Group (CTFG) that is working on how this will be implemented. She is also the co-chair for safety for the EU NTC Curriculum for European regulatory agency assessors and was an EMA expert for the update of the First-in-Human guideline.

    Mariola Fotin-Mleczek

    Chief Scientific Officer., CureVac GmbH
    Mariola Fotin-Mleczek

    Mariola Fotin-Mleczek studied biology at the University of Stuttgart with focus on genetics, cellular biology and immunology.
    She joined CureVac 2006 and was responsible for the preclinical development of mRNA based RNActive technology with the goal to enter first in men clinical studies in tumor patients. In the course of the preclinical development she was responsible for the elucidation of mechanism of action of mRNA-based vaccines. She was critically involved in the number of scientific publications and patents in the field of mRNA-based therapeutics. 2013 she took over the responsibility for the research at CureVac as Chief Scientific Officer. At the moment she coordinates the research of around 50 employees and together with her colleagues in the board of directors refines the strategy of CureVac.
     

    Markus Mandler

    Chief Scientific Officer, Accanis
    Markus  Mandler

    Dr. Mandler is CSO of ACCANIS, bringing with him over 10 years of collaborative research and management experience spanning academia and industry. He completed his PhD at Boehringer Ingelheim´s Institute of Molecular Pathology in Vienna in 2003 working on skin development and especially focused on appendages including hair, feathers, and teeth. Dr. Mandler is the former head of the Neurodegeneration Department at AFFiRiS where he was responsible for developing several immunotherapeutics from preclinic into early clinical development. He has authored numerous publications in high impact journals, several patents and has received multiple national and international research grants for his work.

     

    Nagy Habib

    Chairman and Co-Founder, MiNA Therapeutics
    Nagy Habib

    <p>Professor Nagy Habib is Head of HPB Surgery at the Hammersmith Campus of Imperial College London and also a serial founder and entrepreneur of life sciences ventures. He is co-founder of several biotech companies: EMcision Ltd, OmniCyte Ltd, MiNA Therapeutics Ltd, Apterna Ltd, Medeva Plc and Bioenvision Ltd. Previously he was Pro-Rector for Commercial Affairs at Imperial College London. <br /> He is a translational researcher who pioneered the first clinical trial of the use of plasmid and adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He was the Principal Investigator of world first clinical trials published on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency and CD34+ cells for patients with stroke. <br /> He was the inventor and co-author on the first publication to describe the use of radiofrequency energy in devices for liver surgery (Habib 4X), and interventional endoscopy (Habib&trade; EndoHPB and Habib&trade; EUS-RFA). <br /> Professor Habib holds a gold award from the Advisory Committee for Clinical Excellence which is given to recognise and reward the exceptional contribution of NHS consultants, over and above that normally expected in a job, to the values and goals of the NHS and to patient care, and he was named as one of Britain&rsquo;s top surgeons in December 2011 by the Saturday Times Magazine. <br /> In the 2014 Research Excellence Frame work (REF) exercise, which is the system for assessing the quality of research in UK in higher education institutions, Professor Habib was rated as a 4* researcher which is the highest ranking. His work on radiofrequency ablation was selected among those that have had the most &ldquo;Impact on Society&rdquo; and was ranked 1 with a score of 93%. In January 2015 he was elected as a Foreign Member by the prestigious French Acad&eacute;mie Nationale de Chirurgie.</p> <p>&nbsp;</p>

    Noreen Henig

    Chief Medical Officer, ProQR Therapeutics BV
    Noreen Henig

    Noreen Henig, M.D. has served as our Chief Medical Officer since March 2014. Prior to joining us, Dr. Henig was Senior Director, Global Respiratory, from 2011 to 2014 and Director, Respiratory Therapeutics, from 2008 to 2011, at Gilead Sciences, Inc. Dr. Henig is a board certified physician in Pulmonary, Critical Care and board eligible in Allergy and Immunology and has over 15 years of experience in the cystic fibrosis field and as a director of Adult Cystic Fibrosis Care Centers from 1999 to 2008. Dr. Henig has basic, translational and clinical trial expertise and clinical experience in advanced lung disease including cystic fibrosis, pulmonary arterial hypertension, idiopathic pulmonary fibrosis and lung transplantation. Dr. Henig’s experience at Gilead Sciences, Inc. in drug development includes building and leading a global medical affairs organization, strategic development of clinical trials Phase 2-4, regulatory strategy, corporate development, leadership of key alliances and commercial strategy. Dr. Henig received her medical degree from Albert Einstein College of Medicine of Yeshiva University in 1991 with a distinction in immunology. She also has a bachelor’s degree in History of Art from Yale University.

     

    Oliver Rausch

    VP Research & Development , Storm Therapeutics
    Oliver Rausch

    Oliver Rausch is Vice President Research and Development at Storm Therapeutics. He has overall responsibility for Storm’s biology platform and drug discovery pipeline, and worked closely with Storm’s scientific founders to secure the initial £12M series A investment that launched Storm in 2016.

    Prior to Storm, Oliver was Programme Director at the National Institute for Health Research (NIHR) where he led industry-focussed collaboration initiatives in experimental medicine and early phase clinical trials. He has twenty years of drug discovery experience in Inflammation, Neurology and Oncology gained at Cellzome, UCB and GSK. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.
     

    Samir EL Andaloussi

    Assistant Professor , Karolinska Institutet
    Samir EL Andaloussi

    Samir obtained his PhD in 2008 at Stockholm University and after a postdoctoral stint at Karolinska Institutet working on delivery of RNA-based therapeutics, he joined Prof Matthew Wood´s lab at University of Oxford to work with extracellular vesicles (EVs). Since 2013 Samir is sharing his commitment between Karolinska Institutet as an Assistant professor and at University of Oxford as a departmental research fellow. His lab primarily focuses on developing engineered exosomes for delivery of biotherapeutics to treat genetic diseases. Since a year back, Samir is additionally a co-founder and consultant for Evox Therapeutics that develops EV-based therapeutics.

    Shalini Andersson

    Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D
    Shalini  Andersson

    Shalini is Senior Director and Head of Drug Metabolism & Pharmacokinetics within the Cardiovascular and Metabolic Disease Innovative Medicines unit (CVMD IMED) since December 2010. She is also a member of the Management Team for CVMD IMED as well as of the Review Board for CVMD drug projects. Currently Shalini is also leading Targeted Drug Delivery within CVMD therapy area including the open innovation collaboration with IONIS Pharmaceuticals. She is also the project leader for subcutaneous delivery of modified RNA to man.
    Shalini received her PhD in 1989 at the University of Linköping, Sweden and was a research fellow at the Institute of Pharmaceutical Chemistry, University of Münster, Germany. She joined AstraZeneca in 1997.She is the author or co-author of over 34 peer reviewed articles, 2 book chapters and 4 patents.

     

    Steffen Panzner

    Managing Director, Lipocalyx
    Steffen Panzner

    Dr. Panzner is an expert in oligonucleotide delivery; author of more than 35 patent families and numerous scientific publications covering novel concepts for oligonucleotide delivery such as the Viromer® (virus-mimicking polymer) and the Smarticles® (amphoteric liposome) technology. Products based on these technologies are in phase 2 clinical trials or earlier stages of development.
    Dr. Panzner was Founder and CSO of Novosom AG between 1999 and 2010 and is Founder and CEO of Lipocalyx GmbH which started 2011. He also is a consultant and CMC expert for pharma and biotech companies as well as for VC firms.
     

    Stephen Hart

    Professor in Molecular Genetics, University College London
    Stephen Hart

    Stephen Hart is a Professor in Molecular Genetics at UCL Great Ormond Street Institute of Child Health. He obtained his PhD from the University of Cape Town and has worked in the field of genetic therapies for more than 20 years with more than 100 publications. His current research activities include the development of synthetic nanoparticles for the delivery of nucleic acid therapeutics including siRNA and mRNA for the treatment of paediatric diseases including cystic fibrosis, primary ciliary dyskinesias and neuroblastoma. He is the founder of Nanogenic Solutions Ltd, a UCL spin-out company commercialising siRNA and gene delivery formulations.

    Sponsors and Exhibitors

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Sponsors and Exhibitors


    Phion Therapeutics Ltd

    Sponsors and Exhibitors
    http://www.phiontx.co.uk

    Phion Therapeutics Ltd has developed a peptide nanoparticle for drug delivery that can deliver nucleic acids and other anionic compounds into tumors anywhere in the body at over a 30-fold the concentration relative to normal or healthy cells.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.